China’s Spreading Sunshine Policy Takes On Bloated Drug Receipts
This article was originally published in PharmAsia News
Executive Summary
Manipulation of China’s “fapiao”, or receipt system, is not new but now the State Council is cracking down on the practice, aiming to bring down inflated drug prices. Meanwhile, several provinces are cutting wholesale layers in a wider campaign to squeeze price inflation out of the commercial pharma segment.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
DTP Pharmacies March On In China: Pharma Ignores At Its Own Risk
A shift in dispensing from hospitals to external pharmacies has led to predictions that the direct-to-patient sales model will be big in China. But only those with the right partnerships and expertise will reap the benefits, leading pharmacy chain executives told a recent conference.
Challenges, Opportunities For Cardinal In China Policy Change
Major US pharma distributor Cardinal Health is further expanding its regional presence in China, with the country’s rapidly changing operating environment presenting opportunities and challenges.